Amsterdam, Noord-Holland, The Netherlands In 2010 was created INKEF Capital, which is appeared as VC. The leading representative office of defined VC is situated in the Amsterdam. The company was established in Europe in The Netherlands.
The overall number of key employees were 7.
The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the INKEF Capital, startups are often financed by Union Square Ventures, Life Sciences Partners, Index Ventures. The meaningful sponsors for the fund in investment in the same round are Life Sciences Partners, Healthinnovations, Gilde Healthcare. In the next rounds fund is usually obtained by Keen Venture Partners, Union Square Ventures, Rabobank.
The top amount of exits for fund were in 2018. The real fund results show that this VC is 48 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this INKEF Capital performs on 15 percentage points less the average number of lead investments. The high activity for fund was in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually.
The fund has exact preference in some founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. We can highlight the next thriving fund investment areas, such as Health Care, Biopharma. For fund there is a match between the location of its establishment and the land of its numerous investments - The Netherlands. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight NMD Pharma, Rainier Therapeutics, Shapeways.
Related Funds
Funds with similar focus
Discover 5 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Draupnir Bio | $14M | 17 Jul 2024 | Aarhus, Central Denmark Region, Denmark | ||
iOnctura | $94M | 20 Jun 2024 | Geneva, Geneva, Switzerland | ||
Provable Markets | $8M | 08 May 2024 | New York, New York, United States | ||
Silverflow | $17M | 16 Nov 2023 | Amsterdam, North Holland, Netherlands | ||
NMD Pharma | $88M | 15 Nov 2023 | Aarhus, Central Denmark Region, Denmark | ||
Anavo Therapeutics | $10M | 02 May 2023 | Leiden, South Holland, Netherlands | ||
QurAlis | $88M | 09 Mar 2023 | Cambridge, Massachusetts, United States | ||
Quantum Motion Technologies | $57M | 21 Feb 2023 | Leeds, England, United Kingdom | ||
Happeo | $26M | 07 Jul 2022 | Helsinki, Uusimaa, Finland |
– Cardior Pharmaceuticals from Hanover develops non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases.
– The company closed a €64m ($76m) Series B financing round.
– The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds.
– The new investment will be used for the late-stage clinical development of its lead program and the expansion of its earlier-stage pipeline.
– Castor, a leading provider of clinical trial software, announced the closing of a $45m Series B financing round.
– The round, led by Eight Roads Ventures and F-Prime Capital with participation from existing investors Two Sigma Ventures and Inkef Capital, will fuel continued product development with a particular focus on scaling direct-to-patient trials globally.
– Most clinical trials today require a long set-up time and are conducted at brick-and-mortar research sites which make trial participation inconvenient for patients and leave researchers in the dark about patient data in-between site visits.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Draupnir Bio | $14M | 17 Jul 2024 | Aarhus, Central Denmark Region, Denmark | ||
iOnctura | $94M | 20 Jun 2024 | Geneva, Geneva, Switzerland | ||
Provable Markets | $8M | 08 May 2024 | New York, New York, United States | ||
Silverflow | $17M | 16 Nov 2023 | Amsterdam, North Holland, Netherlands | ||
NMD Pharma | $88M | 15 Nov 2023 | Aarhus, Central Denmark Region, Denmark | ||
Anavo Therapeutics | $10M | 02 May 2023 | Leiden, South Holland, Netherlands | ||
QurAlis | $88M | 09 Mar 2023 | Cambridge, Massachusetts, United States | ||
Quantum Motion Technologies | $57M | 21 Feb 2023 | Leeds, England, United Kingdom | ||
Happeo | $26M | 07 Jul 2022 | Helsinki, Uusimaa, Finland |
